Spots Global Cancer Trial Database for recurrent colon carcinoma

Every month we try and update this database with for recurrent colon carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	NCT03365882	Colon Adenocarc... ERBB2 Gene Ampl... Rectal Adenocar... Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Cetuximab Irinotecan Hydr... Laboratory Biom... Pertuzumab Trastuzumab HER-2 testing	18 Years -	SWOG Cancer Research Network
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer	NCT01198535	Colon Mucinous ... Colon Signet Ri... Rectal Mucinous... Rectal Signet R... Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Cetuximab Gamma-Secretase... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer	NCT01383343	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Bevacizumab Fluorouracil Irinotecan Hydr... Leucovorin Calc... Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer	NCT04294264	Metastatic Colo... Recurrent Colon... Refractory Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon...	Oxaliplatin Trifluridine an...	18 Years -	Rutgers, The State University of New Jersey
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer	NCT01198535	Colon Mucinous ... Colon Signet Ri... Rectal Mucinous... Rectal Signet R... Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Cetuximab Gamma-Secretase... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	NCT04213794	Malignant Abdom... Malignant Pelvi... Recurrent Colon... Recurrent Desmo... Recurrent Fallo... Recurrent Gastr... Recurrent Lipos... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Recurrent Recta... Recurrent Rhabd... Recurrent Sarco... Refractory Colo... Refractory Desm... Refractory Fall... Refractory Gast... Refractory Lipo... Refractory Mali... Refractory Ovar... Refractory Prim... Refractory Rect... Refractory Rhab... Refractory Sarc... Resectable Lipo... Resectable Mali... Resectable Sarc...	Cisplatin Cytoreductive S... Doxorubicin Hyperthermic In... Sodium Thiosulf... Computed Tomogr... Magnetic Resona... Positron Emissi... Biospecimen Col...	1 Year - 25 Years	Mayo Clinic
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer	NCT01383343	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Bevacizumab Fluorouracil Irinotecan Hydr... Leucovorin Calc... Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer	NCT04294264	Metastatic Colo... Recurrent Colon... Refractory Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon...	Oxaliplatin Trifluridine an...	18 Years -	Rutgers, The State University of New Jersey
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer	NCT01729923	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Capecitabine Celecoxib Intensity-Modul... Laboratory Biom... Quality-of-Life... Radiation Thera... Stereotactic Ra... Therapeutic Con...	18 Years -	University of Washington
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	NCT01131234	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Solid Neo... Male Breast Car... Recurrent Adult... Recurrent Breas... Recurrent Colon... Recurrent Melan... Recurrent Non-S... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Stage III Pancr... Stage III Renal... Stage IIIA Colo... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Skin... Stage IIIB Brea... Stage IIIB Colo... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Skin... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Skin... Stage IV Breast... Stage IV Non-Sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Skin M... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Gamma-Secretase... Cediranib Malea... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	NCT04213794	Malignant Abdom... Malignant Pelvi... Recurrent Colon... Recurrent Desmo... Recurrent Fallo... Recurrent Gastr... Recurrent Lipos... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Recurrent Recta... Recurrent Rhabd... Recurrent Sarco... Refractory Colo... Refractory Desm... Refractory Fall... Refractory Gast... Refractory Lipo... Refractory Mali... Refractory Ovar... Refractory Prim... Refractory Rect... Refractory Rhab... Refractory Sarc... Resectable Lipo... Resectable Mali... Resectable Sarc...	Cisplatin Cytoreductive S... Doxorubicin Hyperthermic In... Sodium Thiosulf... Computed Tomogr... Magnetic Resona... Positron Emissi... Biospecimen Col...	1 Year - 25 Years	Mayo Clinic
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery	NCT01802320	Colon Mucinous ... Colon Signet Ri... Rectal Mucinous... Rectal Signet R... Recurrent Colon... Recurrent Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Akt Inhibitor M... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer	NCT01254617	Recurrent Colon... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Recta... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Nasoph... Stage IVA Colon... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Nasal... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Recta... Stage IVB Colon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Nasal... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Recta... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Nasal... Stage IVC Oral ... Stage IVC Oroph... Tongue Carcinom...	Cetuximab Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: